Sign in
Not yet recruitingNo phase

Blood tests to look for markers of diabetic nerve damage

Studies blood samples to find markers of diabetic peripheral neuropathy in adults.

Key facts

Who runs it
Zhejiang Chinese Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Study on Serum Transcriptomics and Metabolomics in Patients With Diabetic Peripheral Neuropathy
Status
Not yet recruiting
People taking part
90 people, planned
Started
20 Mar 2026
Expected to end
30 Jun 2027
Type of study
Observational, 3 groups
Treatments tested
  • Not applicable- observational study
Record updated
8 April 2026

Who can take part

The trial is looking for three groups: people with painful diabetic nerve damage in the legs, people with diabetes but no nerve damage, and healthy volunteers. Blood samples are studied to find markers of diabetic nerve damage.

Age
18 to 80 years
Sex
All sexes
Disease stage
Type 1 or type 2 diabetes. Nerve damage group: lasting pain and/or tingling in both legs, at least one sign of nerve damage on exam, and a DN4 score ≥ 4. Diabetes control group: no nerve damage. Healthy group: no diabetes or nerve damage, of similar age and sex.
Earlier treatment
Healthy volunteers cannot join if they use medicines that affect the nervous system.
Main reasons for not taking part
  • Nerve damage from causes other than diabetes, such as low thyroid, alcohol abuse, medicines or genetic disorders
  • Leg or foot ulcers, gangrene, or past skin ulcers or wounds that did not heal
  • Sudden serious diabetes problems or severe infections in the past 3 months
  • Severe liver, kidney, heart or brain blood vessel disease
  • Pregnancy, breastfeeding or planning pregnancy; another interventional trial in the past 3 months
Show the full registry criteria (17)Hide the full registry criteria

Who can take part

  • Patients diagnosed with diabetes mellitus (type 1 or type 2)
  • For the diabetic peripheral neuropathy (DPN) group: meet diagnostic criteria for painful diabetic peripheral neuropathy (P-DPN), defined as persistent pain and/or paresthesia in both lower limbs, with at least one objective sign of neuropathy (reduced ankle reflex, reduced vibration perception, or abnormal nerve conduction velocity when available), and a DN4 score ≥ 4
  • For the diabetic control (DC) group: patients with diabetes mellitus but no evidence of peripheral neuropathy
  • For the healthy control (HC) group: healthy volunteers without diabetes or neuropathy, matched for sex and age
  • Aged between 18 and 80 years (inclusive)
  • Able to perform activities of daily living independently and cooperate with study procedures
  • No severe cardiac, cerebral, hepatic, renal, or other systemic diseases, and no severe mental illness or cognitive impairment
  • Willing to participate and provide written informed consent

Who cannot take part

  • Participation in another interventional clinical trial within 3 months prior to screening
  • Peripheral neuropathy caused by factors other than diabetes, including but not limited to hypothyroidism, alcohol abuse, medications, genetic disorders, or other systemic diseases
  • Presence of limb ulcers, gangrene, or a history of skin ulceration or non-healing wounds
  • Acute diabetic complications such as diabetic ketoacidosis, hyperosmolar hyperglycemic state, lactic acidosis, or severe infections within the past 3 months
  • Severe hepatic or renal impairment, or severe cardiovascular or cerebrovascular diseases (e.g., unstable angina, myocardial infarction, multiple cerebral infarctions, cerebral hemorrhage)
  • For the healthy control (HC) group: history of diabetes mellitus, peripheral neuropathy, or use of medications affecting neurological function
  • Scars or hyperpigmentation at the testing site that may interfere with accurate measurements
  • Pregnancy, breastfeeding, or planned pregnancy during the study period
  • For the diabetic control (DC) group: presence of peripheral neuropathy

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Diabetic peripheral neuropathy or pain

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This part of the study enrolled 30 sex- and age-matched healthy controls, 30 diabetic patients without peripheral neuropathy, and 30 patients with diabetic peripheral neuropathy (DPN). Blood samples were collected from the participants, and serum was isolated for transcriptomics and untargeted metabolomics analysis using liquid chromatography-mass spectrometry (LC-MS) to characterize the metabolic profile of DPN. Through differential comparison analysis, serum biomarkers associated with DPN were identified and further correlated with clinical parameters. This approach aims to establish early diagnostic markers for DPN and provide scientific evidence for understanding the complex mechanisms underlying DPN, thereby offering new insights into potential therapeutic strategies.

The 3 groups in the trial

  • HC group

    Sex- and age-matched healthy volunteers.

    Treatment: Not applicable- observational study

  • DC group

    Diabetic patients without neuropathy.

    Treatment: Not applicable- observational study

  • DPN group

    Patients with painful diabetic peripheral neuropathy.

    Treatment: Not applicable- observational study

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Study on Serum Transcriptomics and Metabolomics in Patients With Diabetic Peripheral Neuropathy
Plain-language title
Blood tests to look for markers of diabetic nerve damageGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07518433, who can take part
Record updated
8 April 2026